Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR
versus subjects receiving placebo.
Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global
evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric
Rating Scale for Depression, 17-item [HAM-D17] < 7) versus those subjects
receiving placebo.